{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:36:29Z","timestamp":1793810189115,"version":"4.6.1"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.33787","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T08:26:31Z","timestamp":1610612791000},"page":"e2033787","source":"Crossref","is-referenced-by-count":12,"title":["Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer"],"prefix":"10.1001","volume":"4","author":[{"given":"Nataniel H.","family":"Lester-Coll","sequence":"first","affiliation":[{"name":"Division of Radiation Oncology, University of Vermont Larner College of Medicine, Burlington"},{"name":"University of Vermont Cancer Center, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ades","sequence":"additional","affiliation":[{"name":"University of Vermont Cancer Center, Burlington"},{"name":"Division of Hematology and Oncology, University of Vermont Larner College of Medicine, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Atherly","sequence":"additional","affiliation":[{"name":"University of Vermont Cancer Center, Burlington"},{"name":"Center for Health Services Research Department of Medicine, University of Vermont Larner College of Medicine, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"H. James","family":"Wallace","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, University of Vermont Larner College of Medicine, Burlington"},{"name":"University of Vermont Cancer Center, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Sprague","sequence":"additional","affiliation":[{"name":"University of Vermont Cancer Center, Burlington"},{"name":"Department of Surgery, University of Vermont Larner College of Medicine, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"issue":"1","key":"zoi201029r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v70.1","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"zoi201029r2","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/ijcp.2011.65.issue-11","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review.","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"4","key":"zoi201029r3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/pcan.2016.30","article-title":"Increasing incidence of metastatic prostate cancer in the United States (2004-2013).","volume":"19","author":"Weiner","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"zoi201029r4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer.","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi201029r5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer.","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi201029r6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi201029r7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy.","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"10024","key":"zoi201029r8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"zoi201029r9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"10162","key":"zoi201029r10","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"zoi201029r12","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1002\/cncr.31367","article-title":"Alternative payment and care-delivery models in oncology: a systematic review.","volume":"124","author":"Aviki","year":"2018","journal-title":"Cancer"},{"issue":"2","key":"zoi201029r13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020.","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"zoi201029r14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.","volume":"32","author":"Eddy","year":"2012","journal-title":"Med Decis Making"},{"issue":"16","key":"zoi201029r15","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jama.1996.03540160061034","article-title":"Recommendations for reporting cost-effectiveness analyses.","volume":"276","author":"Siegel","year":"1996","journal-title":"JAMA"},{"issue":"1","key":"zoi201029r16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajur.2016.11.005","article-title":"Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer.","volume":"4","author":"Pollard","year":"2017","journal-title":"Asian J Urol"},{"issue":"14","key":"zoi201029r17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/archinte.163.14.1637","article-title":"What is the price of life and why doesn\u2019t it increase at the rate of inflation?","volume":"163","author":"Ubel","year":"2003","journal-title":"Arch Intern Med"},{"issue":"8","key":"zoi201029r18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi201029r19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/01.mlr.0000156862.33341.45","article-title":"Utilities for prostate cancer health states in men aged 60 and older.","volume":"43","author":"Stewart","year":"2005","journal-title":"Med Care"},{"issue":"18","key":"zoi201029r20","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2014.14950","article-title":"Association between the Medicare hospice benefit and health care utilization and costs for patients with poor-prognosis cancer.","volume":"312","author":"Obermeyer","year":"2014","journal-title":"JAMA"},{"issue":"18","key":"zoi201029r21","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1200\/JCO.2017.75.5371","article-title":"Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer.","volume":"36","author":"Pan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi201029r22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Making"},{"issue":"7210","key":"zoi201029r23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/bmj.319.7210.635","article-title":"Handling uncertainty in economic evaluations of healthcare interventions.","volume":"319","author":"Briggs","year":"1999","journal-title":"BMJ"},{"issue":"13","key":"zoi201029r26","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jama.2009.1409","article-title":"Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.","volume":"302","author":"Clement","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"zoi201029r27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ijrobp.2016.01.020","article-title":"Cost-effectiveness of surgery, stereotactic body radiation therapy, and systemic therapy for pulmonary oligometastases.","volume":"95","author":"Lester-Coll","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"zoi201029r28","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/COC.0000000000000608","article-title":"Cost-effectiveness analysis of upfront SBRT for oligometastatic stage IV non-small cell lung cancer based on mutational status.","volume":"42","author":"Kim","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"zoi201029r29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.radonc.2018.07.017","article-title":"A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).","volume":"129","author":"Panje","year":"2018","journal-title":"Radiother Oncol"},{"key":"zoi201029r30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2020.09.045","article-title":"Cost-effectiveness analysis of stereotactic ablative radiation therapy in patients with oligometastatic cancer.","author":"Kumar","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"zoi201029r31","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.ijrobp.2020.06.009","article-title":"Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer.","volume":"108","author":"Parikh","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi201029r32","article-title":"Oncology\u2019s \u201chockey stick\u201d moment for the cost of cancer drugs: the climate is about to change.","author":"Polite","year":"2020","journal-title":"JAMA Oncol"},{"key":"zoi201029r33","doi-asserted-by":"publisher","first-page":"c117","DOI":"10.1136\/bmj.c117","article-title":"Is a subgroup effect believable? updating criteria to evaluate the credibility of subgroup analyses.","volume":"340","author":"Sun","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"zoi201029r35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.prro.2020.02.014","article-title":"Costs and complications after a diagnosis of prostate cancer treated with time-efficient modalities: an analysis of national Medicare data.","volume":"10","author":"Tang","year":"2020","journal-title":"Pract Radiat Oncol"},{"issue":"42","key":"zoi201029r36","doi-asserted-by":"publisher","first-page":"71548","DOI":"10.18632\/oncotarget.v8i42","article-title":"A global comparison of the cost of patented cancer drugs in relation to global differences in wealth.","volume":"8","author":"Goldstein","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"zoi201029r37","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1001\/jama.2018.1150","article-title":"Health care spending in the United States and other high-income countries.","volume":"319","author":"Papanicolas","year":"2018","journal-title":"JAMA"},{"key":"zoi201029r34","author":"Mak","year":"2016"},{"key":"zoi201029r11","unstructured":"National Comprehensive Cancer Network. Prostate cancer, version 2. Accessed July 02, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"zoi201029r24","unstructured":"US Department of Labor. Inflation & prices online calculator: Bureau of Labor Statistics. Published in 2020. Accessed July 02, 2020. https:\/\/www.bls.gov\/data\/#calculators"},{"key":"zoi201029r25","unstructured":"Centers for Medicare & Medicaid Services. What Are the value-based programs? Accessed November 13, 2020. https:\/\/www.cms.gov\/Medicare\/Quality-Initiatives-Patient-Assessment-Instruments\/Value-Based-Programs\/Value-Based-Programs"},{"key":"zoi201029r38","unstructured":"Lexicomp. Apalutamide. Accessed July 2, 2020. http:\/\/online.lexi.com\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2774904\/lestercoll_2021_oi_201029_1612208605.56506.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T03:29:52Z","timestamp":1612841392000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2774904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.33787","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]}}}